Dietary γ-tocopherol-rich mixture inhibits estrogen-induced mammary tumorigenesis by modulating estrogen metabolism, antioxidant response, and PPARγ

Cancer Prevention Research

Volumn 8, Issue 9, 2015, Pages 807-816

  Das Gupta, Soumyasri ^a   Sae Tan, Sudathip ^a   Wahler, Joseph ^a   So, Jae Young ^a   Bak, Min Ji ^a   Cheng, Larry C ^a   Lee, Mao Jung ^a   Lin, Yong ^b,c   Shih, Weichung Joe ^b,c   Shull, James D ^d   Safe, Stephen ^e   Yang, Chung S ^a,c   Suh, Nanjoo ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTRADIOL; GAMMA TOCOPHEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIOXIDANT; CDKN1B PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; ESTROGEN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN F2 ALPHA; PTEN PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; DRUG MECHANISM; ESTROGEN METABOLISM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELL LINE; METABOLISM; NUDE MOUSE; TIME FACTOR; TUMOR CELL LINE; UDDER;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DINOPROST; ESTRADIOL; ESTROGENS; FEMALE; GAMMA-TOCOPHEROL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXIDATIVE STRESS; PPAR GAMMA; PROLIFERATING CELL NUCLEAR ANTIGEN; PTEN PHOSPHOHYDROLASE; RATS; RNA, MESSENGER; TIME FACTORS;

EID: 84941752058     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0154     Document Type: Article

References (50)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
3. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63-78.
4. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
5. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad Sci 2006;1089:286-301.
6. Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 2013;78:161-70.
7. Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008;21:93-101.
8. Fussell KC, Udasin RG, Smith PJ, Gallo MA, Laskin JD. Catechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells. Carcinogenesis 2011;32:1285-93.
9. Wang Z, Chandrasena ER, Yuan Y, Peng KW, Van Breemen RB, Thatcher GR, et al. Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens. Chem Res Toxicol 2010;23:1365-73.
10. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci U S A 2003;100:3913-8.
11. Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, Hei TK, et al. Estrogeninduced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 2008;232:78-85.
12. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008;122:1949-57.
13. Singh B, Bhat NK, Bhat HK. Induction of NAD (P) H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer. Carcinogenesis 2012;33:156-63.
14. Singh B, Bhat HK. Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer. Carcinogenesis 2012;33:2601-10.
15. Constantinou C, Papas A, Constantinou AI. Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2008;123:739-52.
16. Ju J, Picinich SC, Yang Z, Zhao Y, Suh N, Kong AN, et al. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis 2010;31:533-42.
17. Yang CS, Suh N, Kong A-NT. Does vitamin E prevent or promote cancer? Cancer Prev Res 2012;5:701-5.
18. Weinstein SJ, Peters U, Ahn J, Friesen MD, Riboli E, Hayes RB, et al. Serum a-tocopherol and g-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study. PLoS One 2012;7:e40204.
19. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65.
20. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009;301:52-62.
21. Jiang Q, Christen S, Shigenaga MK, Ames BN. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001;74:714-22.
22. Ju J, Hao X, Lee MJ, Lambert JD, Lu G, Xiao H, et al. A gamma-tocopherolrich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice. Cancer Prev Res 2009;2:143-52.
23. Lu G, Xiao H, Li G-X, Picinich SC, Chen Y-K, Liu A, et al. A g-tocopherol-rich mixture of tocopherols inhibits chemically induced lung tumorigenesis in A/J mice and xenograft tumor growth. Carcinogenesis 2010;31:687-94.
24. Lee HJ, Ju J, Paul S, So JY, De Castro A, Smolarek A, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 2009;15:4242-9.
25. Smolarek AK, So JY, Burgess B, Kong AN, Reuhl K, Lin Y, et al. Dietary administration of delta- and gamma-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor-positive, but not HER-2 breast cancer. Cancer Prev Res 2012;5:1310-20.
26. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL. Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly developmammary carcinoma. Carcinogenesis 1997;18:1595-601.
27. Das Gupta S, So JY, Wall B, Wahler J, Smolarek AK, Sae-Tan S, et al. Tocopherols inhibit oxidative and nitrosative stress in estrogen-induced early mammary hyperplasia in ACI rats. Mol Carcinog 2014 Apr. 30. doi: 10.1002/mc.22164. [Epub ahead of print].
28. Smolarek AK, So JY, Thomas PE, Lee HJ, Paul S, Dombrowski A, et al. Dietary tocopherols inhibit cell proliferation, regulate expression of ERalpha, PPARgamma, and Nrf2, and decrease serum inflammatory markers during the development of mammary hyperplasia. Mol Carcinog 2013;52:514-25.
29. Turan VK, Sanchez RI, Li JJ, Li SA, Reuhl KR, Thomas PE, et al. The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol 2004;183:91-9.
30. Zhao Y, Lee MJ, Cheung C, Ju JH, Chen YK, Liu B, et al. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J Agric Food Chem 2010;58:4844-52.
31. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, Uskokovic M, et al. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 2006;72:332-43.
32. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001;142:4120-30.
33. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
34. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
35. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, et al. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc Natl Acad Sci US A 1997;94:10937-42.
36. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) 2012;26:688-94, 96.
37. Aiyer HS, Gupta RC. Berries and ellagic acid prevent estrogen-induced mammary tumorigenesis bymodulating enzymes of estrogen metabolism. Cancer Prev Res 2010;3:727-37.
38. Kurz SG, Hansen KK, McLaughlin MT, Shivaswamy V, Schaffer BS, Gould KA, et al. Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat. Endocrinology 2008;149:3850-9.
39. Clarke MW, Ward NC, Wu JH, Hodgson JM, Puddey IB, Croft KD. Supplementation with mixed tocopherols increases serum and blood cell g-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes. Am J Clin Nutr 2006;83:95-102.
40. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999;130:270-7.
41. Samavat H, Kurzer MS. Estrogenmetabolismand breast cancer. Cancer Lett 2015;356:231-43.
42. Jin U-H, Lee S-O, Safe S. Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells. J Pharmacol Exp Ther 2012;343:333-41.
43. Spink DC, Spink BC, Cao JQ, De Pasquale JA, Pentecost BT, Fasco MJ, et al. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 1998;19:291-8.
44. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791-800.
45. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012;12:564-71.
46. Gaikwad NW, Rogan EG, Cavalieri EL. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 2007;43:1289-98.
47. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003;9:1-9.
48. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009;8:6-15.
49. Campbell SE, Musich PR, Whaley SG, Stimmel JB, Leesnitzer LM, Dessus-Babus S, et al. Gamma tocopherol upregulates the expression of 15-S-HETE and induces growth arrest through a PPAR gammadependent mechanism in PC-3 human prostate cancer cells. Nutr Cancer 2009;61:649-62.
50. Campbell SE, Stone WL, Whaley SG, Qui M, Krishnan K. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer 2003;3:25.